Alkermes Unveils Phase 1b Data for Narcolepsy Treatment at SLEEP 2024
Portfolio Pulse from Benzinga Newsdesk
Alkermes plc (NASDAQ:ALKS) announced new data from a phase 1b study of ALKS 2680, an investigational treatment for narcolepsy type 1, at the SLEEP 2024 conference. The study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in ten patients.
June 03, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alkermes presented new data from a phase 1b study of ALKS 2680, showing promising results for its narcolepsy treatment. This could positively impact the stock price in the short term.
The presentation of positive phase 1b data for ALKS 2680 at a major conference could generate investor interest and optimism, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100